作者:K. Ravikumar、B. Sridhar、M. Mahesh、V. V. Narayana Reddy
DOI:10.1007/s10870-006-9078-4
日期:2006.6
The crystal structures of isoxazole, 3-[[dihydro-2-[(Z)-2-oxohyrazono]-1H-imidazol-1-(3H)-yl]methyl-5-phenyl-,N-oxide] (C13H13N5O3) (I), isoxazole,3-[[dihydro-2-[(Z)-2-oxohyrazono]-1H-imidazol-1-(3H)-yl]-methyl-5-(4-methylphenyl)-,N-oxide] (C14H15N5O3) (II) and isoxazole, 3-[[dihydro-2-[(Z)-2-oxohyrazono]-1H-imidazol-1-(3H)-yl]-methyl-5-(2-methoxyphenyl)-,N-oxide] (C14H15N5O4) (III) have been determined by X-ray diffraction studies. The compound I, crystallized in triclinic space group $$P\bar 1$$ with unit cell dimensions a = 7.2405(7) Å, b = 7.9936(8) Å, c = 11.6573(11) Å, α = 97.801(2)°, β = 90.884(2)°, γ = 96.250(2)° and Z = 2. Compound II crystallized in orthorhombic space group Pna21 with unit cell dimensions a = 10.1778(10) Å, b = 28.228(3) Å, c = 5.1206(5) Å, and Z = 4. Compound III crystallized in monoclinic space group P21/n with unit cell dimensions a = 7.8439(9) Å, b = 7.8544(9) Å, c = 23.534(3) Å, β = 99.464(2)° and Z = 4. For all three compounds, the five-membered imidazolidine ring adopts an envelope conformation. The crystal structures are stabilized by both the intramolecular N–H···O and intermolecular N–H···N hydrogen bonding.
(C13H13N5O3) (I), isoxazole,3-[[dihydro-2-[(Z)-2-oxohyrazono]-1H-imidazol-1-(3H)-yl]-methyl-5-(4-methylphenyl)-,N-oxide](C14H15N5O3) (II) and isoxazole, 3-[[dihydro-2-[(Z)-2-oxohyrazono]-1H-imidazol-1-(3H)-yl]-methyl-5-(2-methoxyphenyl)-,N-oxide](C14H15N5O4) (III) 已通过 X 射线衍射研究确定。化合物 I 结晶于三linic 空间群 $$P\bar 1$$,单胞尺寸 a = 7.2405(7) 埃,b = 7.9936(8) 埃,c = 11.6573(11) 埃,α = 97.801(2)°,β = 90.884(2)°,γ = 96.250(2)°,Z = 2。化合物 II 结晶为正交空间群 Pna21,单胞尺寸 a = 10.1778(10) 埃,b = 28.228(3) 埃,c = 5.1206(5) 埃,Z = 4。化合物 III 结晶于单斜空间群 P21/n,单胞尺寸 a = 7.8439(9) 埃,b = 7.8544(9) 埃,c = 23.534(3) 埃,β = 99.464(2)°,Z = 4。所有这三种化合物的五元咪唑烷环都采用了包络构象。分子内的 N-H-O 和分子间的 N-H-N 氢键都稳定了晶体结构。